Going back to this study: https://www.frontiers

Going back to this study:

https://www.frontiersin.org/articles/10.3389/...;id=794638

Isn't the quote below and many others found therein:

Quote:

---

Therefore, we next sought to assess the impact of Leronlimab on CCR5+CD4+ T cells levels in both peripheral blood and within tissues. Following administration of Leronlimab at either dose we observed an increase in the frequencies of CCR5+CD4+ T cells circulating within peripheral blood that tracked with CCR5 RO (Figure 3C). In line with the rapid stabilization of CCR5 in vitro shown in Figure 1, statistically significant increases in peripheral blood CCR5+CD4+ T cell frequencies were found as early as eight hours post injection and maintained at every timepoint examined throughout the first week post injection (Figure 3D). Next, we examined the impact of Leronlimab on CCR5+CD4+ T cells from lymph node and bone marrow biopsies. Similar to peripheral blood results, we found no CCR5 RO on lymph node and bone marrow CD4+ T cells prior to Leronlimab injection, followed by high levels of CCR5 RO on CD4+ T cells from these tissues at one week post injection (Figure 3E).

---

strikingly similar to what Dr.Otto Yang found out in the Long Haulers study with the finding of increasing quantities of CCR5 receptors found on the surfaces of CD4 and CD8 cells in those patients who responded to LL treatment?

Notice Scott Kelly, Chris Recknor, Nader Poorhassan and Jonah Sacha are listed as authors. This tendency to increase not only the CCR5 receptors on the surfaces, but also the quantities of CD4 cells, with CCR5 had been known to happen with LL administration since this articles date November 19, 2021.

Bruce Patterson was saying LL works by reducing inflammation, by taming the immune system and these findings showing that the immune system was being ramped up with LL administration by somehow inducing a response to increase quantity of T cells in the peripheral blood and lymphatic system.

Otto Yang said:

Quote:

---

“But we found just the opposite,” Yang said. “Patients who improved were those who started with low CCR5 on their T cells, suggesting their immune system was less active than normal, and levels of CCR5 actually increased in people who improved. This leads to the new hypothesis that long COVID in some persons is related to the immune system being suppressed and not hyperactive, and that while blocking its activity, the antibody can stabilize CCR5 expression on the cell surface leading to upregulation of other immune receptors or functions.”

---

BPs test kit could not accurately predict whether LL would work or not, because it was found that those patients who actually did respond, had abnormally low CCR5 on the surfaces, but after treatment, had increased to normal levels suggesting an increased capacity of the immune system with LL administration. If he saying that LL would only work in patients with high numbers of CCR5 to begin with, he would have missed all the patients who actually responded to LL. BP test would have ruled in the non responders and ruled out the responders. Exactly the opposite of what you want for a successful test.,

Otto's findings are quite similar to the findings in HIV where LL administration induced increased number of CD4 cells along with more CCR5.

By that remark, I'd say he was not impressed with Otto's findings and for that matter what SK, CR, NP and JS found. He was applauding as a matter of course, rather than sincerely.